Publications by authors named "Fanglei You"

Claim this Profile
B
BT7480, a novel fully synthetic tumor-targeted immune cell agonist™ ( TICA™) induces tumor localized CD137 agonism.
Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Eric Haines, Heather Cohen, Fanglei You

J Immunother Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.
Punit Upadhyaya, Johanna Lahdenranta, Kristen Hurov, Sailaja Battula, Rachel Dods, Fanglei You

J Immunother Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased systolic load causes adverse remodeling of fetal aortic and mitral valves.
Frederick A Tibayan, Samantha Louey, Sonnet Jonker, Herbert Espinoza, Natasha Chattergoon, Fanglei You

Am J Physiol Regul Integr Comp Physiol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional profiling of rapamycin-treated fibroblasts from hypertrophic and keloid scars.
Victor W Wong, Fanglei You, Michael Januszyk, Geoffrey C Gurtner, Anna A Kuang

Ann Plast Surg· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tacrolimus fails to regulate collagen expression in dermal fibroblasts.
Victor W Wong, Fanglei You, Michael Januszyk, Anna A Kuang

J Surg Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells.
Fanglei You, Lisa A Roberts, S Peter Kang, Raquel A Nunes, Cinara Dias

J Hematol Oncol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
Lyndsay N Harris, Fanglei You, Stuart J Schnitt, Agnes Witkiewicz, Xin Lu

Clin Cancer Res· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells.
Fanglei You, Natsuko Chiba, Chikashi Ishioka, Jeffrey D Parvin

Oncogene· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis